NCT01794793 2024-10-01Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored StudiesRECORDATI GROUPPhase 4 Completed337 enrolled 8 charts
NCT01689727 2023-06-22Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary TumorsEndocytePhase 2 Completed40 enrolled
NCT01915303 2020-09-18Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's DiseaseNovartisPhase 2 Terminated68 enrolled 25 charts
NCT04335357 2020-04-06TBR-760 in Adult Patients With Non-Functioning Pituitary AdenomasTiburio TherapeuticsPhase 2 Unknown150 enrolled
NCT01673646 2019-09-16Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary GigantismNovartisPhase 2 Completed33 enrolled 24 charts
NCT00376064 2017-03-06Efficacy of Octreotide Acetate and Cabergoline in Patients With AcromegalyNovartisPhase 4 Completed20 enrolled
NCT00958841 2016-07-26Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine OriginNovartisPhase 2 Terminated118 enrolled 11 charts
NCT00006368 2013-05-01Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent CancerNovartisPhase 1 Completed60 enrolled